Abivax SA (0RA9)
LSE
Closed
Aug 25, 2026
Day's Range
100.8052 wk Range
60.70Overview - 0RA9 - Abivax SA
Key Statistics
Valuation
Enterprise Value
7.61B
Price / Book
‪18.14‬
EV / EBITDA
‪-29.97‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-4,183.70%‬
Return on Assets
‪-44.65%‬
Return on Equity
‪-157.06%‬
Ownership
Shares Outstanding
9.98M
Float
70.13M
Held by Insiders
‪4.84%‬
Held by Institutions
‪50.10%‬
Price stats
Beta
‪-0.22‬
50-Day Avg
‪11.44‬
200-Day Avg
‪13.25‬
Market Cap - 0RA9 - Abivax SA
Peers - 0RA9 - Abivax SA
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0RA9LSEAbivax SA981.11MMarket Cap+33.20%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated141.26BMarket Cap+29.99%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA45.60BMarket Cap+11.01%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0RA9 - Abivax SA
About
Abivax SA is a France-based clinical-stage biotechnology company dedicated to developing innovative therapeutics that modulate the immune response in patients with chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms, particularly through enhanced expression of microRNA-124. Its lead…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
